Cargando…

Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty

SIMPLE SUMMARY: Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of muscle strength and muscle mass. It associated with reduced physical function and negative outcomes such as falls, hospitalization, loss of autonomy, disability, and mortality. Sarcopenia has boug...

Descripción completa

Detalles Bibliográficos
Autores principales: Colloca, Giuseppe Ferdinando, Bellieni, Andrea, Di Capua, Beatrice, Iervolino, Marialuisa, Bracci, Serena, Fusco, Domenico, Tagliaferri, Luca, Landi, Francesco, Valentini, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527381/
https://www.ncbi.nlm.nih.gov/pubmed/37760569
http://dx.doi.org/10.3390/cancers15184600
_version_ 1785111144876212224
author Colloca, Giuseppe Ferdinando
Bellieni, Andrea
Di Capua, Beatrice
Iervolino, Marialuisa
Bracci, Serena
Fusco, Domenico
Tagliaferri, Luca
Landi, Francesco
Valentini, Vincenzo
author_facet Colloca, Giuseppe Ferdinando
Bellieni, Andrea
Di Capua, Beatrice
Iervolino, Marialuisa
Bracci, Serena
Fusco, Domenico
Tagliaferri, Luca
Landi, Francesco
Valentini, Vincenzo
author_sort Colloca, Giuseppe Ferdinando
collection PubMed
description SIMPLE SUMMARY: Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of muscle strength and muscle mass. It associated with reduced physical function and negative outcomes such as falls, hospitalization, loss of autonomy, disability, and mortality. Sarcopenia has bought value in the cancer management, given its impact on patients’ treatments and prognosis. In hematologic diseases, sarcopenia predicts toxicity, treatment’s response, influences overall survival and non-cancer-related risk of death. Diagnosing and properly framing sarcopenia is of great importance in designing the patient appropriate treatment and to perform a personalized or “tailor made” approach and supportive care. Early recognize sarcopenia allows to reverse the muscle loss process and to avoid negative impacts of sarcopenia syndrome on the patients’ trajectory. ABSTRACT: Sarcopenia is a geriatric syndrome characterized by a progressive loss of systemic muscle mass and decreased muscle strength or physical function. Several conditions have a role in its pathogenesis, significantly impacting adverse outcomes such as falls, functional decline, frailty, disability, multiple hospitalizations, and mortality. In the oncological setting, sarcopenia is associated with an increased risk of treatment toxicity, postoperative complications, and a higher mortality rate related to other causes (e.g., pneumonia). In the hematological field, even more so, sarcopenia predicts toxicity and response to treatments. In patients with hematologic malignancy, low muscle mass is associated with adverse outcomes and is a predictor of overall survival and non-relapse mortality. Therefore, it is essential to correctly recognize sarcopenia, evaluate the risk factors and their impact on the patient’s trajectory, and effectively treat sarcopenia. Sarcopenia is a reversible condition. The most effective intervention for reversing it is physical exercise combined with nutrition. The objective of clinical assessment focused on sarcopenia is to be able to carry out a “tailor-made treatment”.
format Online
Article
Text
id pubmed-10527381
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105273812023-09-28 Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty Colloca, Giuseppe Ferdinando Bellieni, Andrea Di Capua, Beatrice Iervolino, Marialuisa Bracci, Serena Fusco, Domenico Tagliaferri, Luca Landi, Francesco Valentini, Vincenzo Cancers (Basel) Review SIMPLE SUMMARY: Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of muscle strength and muscle mass. It associated with reduced physical function and negative outcomes such as falls, hospitalization, loss of autonomy, disability, and mortality. Sarcopenia has bought value in the cancer management, given its impact on patients’ treatments and prognosis. In hematologic diseases, sarcopenia predicts toxicity, treatment’s response, influences overall survival and non-cancer-related risk of death. Diagnosing and properly framing sarcopenia is of great importance in designing the patient appropriate treatment and to perform a personalized or “tailor made” approach and supportive care. Early recognize sarcopenia allows to reverse the muscle loss process and to avoid negative impacts of sarcopenia syndrome on the patients’ trajectory. ABSTRACT: Sarcopenia is a geriatric syndrome characterized by a progressive loss of systemic muscle mass and decreased muscle strength or physical function. Several conditions have a role in its pathogenesis, significantly impacting adverse outcomes such as falls, functional decline, frailty, disability, multiple hospitalizations, and mortality. In the oncological setting, sarcopenia is associated with an increased risk of treatment toxicity, postoperative complications, and a higher mortality rate related to other causes (e.g., pneumonia). In the hematological field, even more so, sarcopenia predicts toxicity and response to treatments. In patients with hematologic malignancy, low muscle mass is associated with adverse outcomes and is a predictor of overall survival and non-relapse mortality. Therefore, it is essential to correctly recognize sarcopenia, evaluate the risk factors and their impact on the patient’s trajectory, and effectively treat sarcopenia. Sarcopenia is a reversible condition. The most effective intervention for reversing it is physical exercise combined with nutrition. The objective of clinical assessment focused on sarcopenia is to be able to carry out a “tailor-made treatment”. MDPI 2023-09-16 /pmc/articles/PMC10527381/ /pubmed/37760569 http://dx.doi.org/10.3390/cancers15184600 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Colloca, Giuseppe Ferdinando
Bellieni, Andrea
Di Capua, Beatrice
Iervolino, Marialuisa
Bracci, Serena
Fusco, Domenico
Tagliaferri, Luca
Landi, Francesco
Valentini, Vincenzo
Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title_full Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title_fullStr Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title_full_unstemmed Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title_short Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
title_sort sarcopenia diagnosis and management in hematological malignancies and differences with cachexia and frailty
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527381/
https://www.ncbi.nlm.nih.gov/pubmed/37760569
http://dx.doi.org/10.3390/cancers15184600
work_keys_str_mv AT collocagiuseppeferdinando sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT bellieniandrea sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT dicapuabeatrice sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT iervolinomarialuisa sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT bracciserena sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT fuscodomenico sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT tagliaferriluca sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT landifrancesco sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty
AT valentinivincenzo sarcopeniadiagnosisandmanagementinhematologicalmalignanciesanddifferenceswithcachexiaandfrailty